MMP9 and triple-A syndrome: Moreover, the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, has been shown to suppress MMP-9 production in the aortic wall in humans [147] and prevent aneurysm formation in an elastase-induced AAA model in rats [148].